AccurKardia

AccurKardia

软件开发

New York,NY 1,369 位关注者

ECG-led Diagnostics

关于我们

AccurKardia is an ECG-led diagnostics software company transforming ECG signals into a broad biomarker and diagnostic tool for disease management in cardiology and beyond. Our mission is to improve patient outcomes and save lives on a global scale. Our flagship product, AccurECG?, is an FDA-cleared (Class II SaMD), cloud-based, device-agnostic software providing fully automated ECG interpretation, capable of detecting up to 13 arrhythmias. It assists cardiac monitoring companies in analyzing ECGs from holters, event recorders, and cardiac telemetry devices, significantly enhancing efficiency and patient care. Recently, AccurKardia reached a major milestone with the FDA Breakthrough Device Designation for our AI-driven ECG-based Aortic Valve Stenosis (AK-AVS) screening software. This achievement highlights our dedication to advancing early detection and precision medicine in cardiovascular care. We are also proud participants in the MedTech Innovator 2024 Cohort and the Heart & Brain Health Accelerator track, in collaboration with the American Heart Association’s Center for Health Technology and Innovation.

网站
https://www.accurkardia.com
所属行业
软件开发
规模
11-50 人
总部
New York,NY
类型
私人持股
创立
2019
领域
artificial intelligence、AI、cardiac healthcare、ecg analysis、healthtech、medtech、IoT、digitalhealth、medical devices、remote patient monitoring、diagnostics、biomarker和EKG

地点

  • 主要

    101 Avenue of the Americas

    US,NY,New York,10013

    获取路线

AccurKardia员工

动态

相似主页

查看职位

融资